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INTRODUCTION
Bacterial cancer therapy relies on bacteria that can target solid 
tumors and proliferate therein (reviewed in refs. 1–3). Although the 
mechanism underlying this phenomenon has yet to be understood, 
an immune-privileged environment in tumor tissue should offer a 
sanctuary for intratumoral bacteria, which can proliferate up to 109 
colony forming unit/g tissue.1,4 Such bacterial proliferation, espe-
cially that of Salmonella spp. or Clostridium spp., results in tumor 
regression.5–7 Bacteria equipped with anticancer cargo proteins are 
often more effective tumor suppressors than bacterial monother-
apy.8–10 Such anticancer proteins include cytotoxic agents, cytokines 
that stimulate immune cells to kill cancer cells, and tumor antigens 
that sensitize the immune system against cancer cells.1,11 Since 
most, if not all, of the anticancer proteins are more or less toxic to 
normal cells, they should be expressed exclusively in intratumoral 
bacteria.12–15
Asparaginase (L-ASNase) of Escherichia coli origin is a universal 
component of therapy for acute lymphoblastic leukemia.16 L-ASNase 
catalyzes the deamination of asparagine to aspartate and to a lesser 
extent the deamination of glutamine to glutamate.17 Both activi-
ties may be needed for therapeutic effectiveness against malig-
nancies.17,18 Asparagine depletion leads to an adaptive response 
in which uncharged tRNA activates the serine/threonine kinase 
GCN2 (ref. 19). GCN2 phosphorylates the translation initiation factor 
eIF2á, which acts as a dominant inhibitor of the guanine nucleotide 
exchange factor eIF2B, which prevents eIF2 recycling during protein 
synthesis, resulting in inhibition of global protein synthesis.20 Unless 
asparagine can be resynthesized rapidly enough to keep its tRNA 
charged, cells undergo apoptotic cell death for a downregulation of 
the overall rate of protein synthesis.21
The glutaminase activity of L-ASNase also promotes apoptosis. 
A high intracellular glutamine concentration promotes the uptake of 
leucine which stimulates protein synthesis by activating mTORC1.22 
The reduction of mTORC1 activity when glutamine is low suppresses 
protein synthesis and augments the effects of asparagine deficiency 
on apoptosis. Furthermore, mitochondrial catabolism of glutamine 
can rescue tumor cells from asparagine deficiency by providing the 
four carbons and two nitrogens required for asparagine synthesis.23 
What’s more, glutamine is required for the resynthesis of asparagine 
from aspartate by asparagine synthetase (ASNS).24 ASNS expres-
sion is normally low in cells but activation of the GCN2-eIF2á sys-
tem promotes translation of the transcription factor ATF4 (ref. 25) 
which induces ASNS expression. Provided sufficient glutamine is 
present, ASNS can promote asparagine accumulation which sup-
presses GCN2 and rescues the cells from apoptosis. L-ASNase has 
been used successfully to treat blood borne acute lymphoblastic 
leukemia tumors via intravenous (i.v.) administration26 because res-
cue circuits fail in acute lymphoblastic leukemia cells.27,28 Prior to this 
study, it was rarely possible to treat solid tumors with L-ASNase,29 
in part because systemic treatment with the high concentrations 
of L-ASNase needed to affect the asparagine concentration in the 
tumor is frequently accompanied by serious side-effects including 
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Bacteria can be engineered to deliver anticancer proteins to tumors via a controlled expression system that maximizes the con-
centration of the therapeutic agent in the tumor. L-asparaginase (L-ASNase), which primarily converts asparagine to aspartate, is 
an anticancer protein used to treat acute lymphoblastic leukemia. In this study, Salmonellae were engineered to express L-ASNase 
selectively within tumor tissues using the inducible araBAD promoter system of Escherichia coli. Antitumor efficacy of the engi-
neered bacteria was demonstrated in vivo in solid malignancies. This result demonstrates the merit of bacteria as cancer drug 
delivery vehicles to administer cancer-starving proteins such as L-ASNase to be effective selectively within the microenvironment 
of cancer tissue.
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anaphylactic shock, coagulopathies as well as liver and pancreatic 
toxicity.30 Furthermore, it has been thought that upregulation of 
ASNS would rescue the tumor from apoptosis.31 However, in this 
study, Salmonellae was engineered to express large amounts of 
L-ASNase (EC2) of E. coli origin selectively within solid tumors using 
a remote gene control system derived from araPBAD inducible by sys-
temic administration lf soluble activator, L-arabinose.8 This is the first 
demonstration of antitumor efficacy of targeted L-ASNasein solid 
tumor models.
ReSUlTS
Cytotoxicity associated with L-ASNase expressed from Salmonellae 
in vitro
In an attempt to treat solid malignancies with L-ASNase, we con-
structed a plasmid, pASN, carrying the asnB gene of E. coli B (BL21) 
under the control of the araBAD promoter(PBAD) of the E. coli arabi-
nose operon, which is inducible by L-arabinose, by cloning the 
1,047 bp PCR-amplified asnB open reading frame into GlmS+p 
(Supplementary Figure S1a).32 The GlmS+p is a balanced lethal 
host vector system32 that relies on the phenotype of the GlmS- 
mutant. This mutant undergoes lysis when grown in the absence 
of N-acetyl-D-glucosamine (GlcNac) unless complemented by a 
plasmid carrying the glmS gene.32 We used a highly attenuated 
S.  typhimurium strain (14028s) defective in ppGpp synthesis33and 
carrying a mutation in the glmS gene (ΔppGpp S. typhimurium), 
and transformed it with pASN. The Salmonellae were grown in Luria 
Broth supplemented with L-arabinose (0.2%; ref. 34). The bacterial 
culture was harvested, the supernatant medium was separated 
from the cells by centrifugation and filtration, and each fraction 
was analyzed for L-ASNase by western blotting using a specific 
antibody (Supplementary Figure  S1b). L-ASNase was induced by 
the L-arabinose supplementation. Moreover, a significant fraction 
of L-ASNase was secreted, and thus found in the supernatant, as 
in E. coli.35 Subsequently, proteins in the culture supernatant were 
tested for L-ASNase activity by measuring cytotoxicity in three 
cultured cancer cell lines: mouse MC38 colon cancer cells, mouse 
4T-1 breast cancer cells, and human AsPC-1 pancreatic cancer cells 
(Figure 1). The Jurkat T-cell leukemia line and the immortalized 
noncancerous HEK293 kidney cell line, sensitive and insensitive, 
respectively, to L-ASNase, were included as positive and nega-
tive controls, respectively. The cells were exposed for 24, 48, and 
72 hours to the concentrated culture supernatants (0.2 mg/ml) of 
Salmonella carrying parental plasmid (glmS+p) or pASN, and cell 
death was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- 
tetrazolium bromide (MTT) assay. All cell lines except HEK293 
showed varying degrees of sensitivity (60–80%) to L-ASNase-
containing bacterial culture supernatant and to L-ASNase used clini-
cally (Leunase, 5 units/ml, Kyowa Hakko Kirin, Japan). By contrast, 
only marginal cytotoxicity was observed upon exposure to the 
culture supernatant of Salmonella carrying glmS+p, confirming the 
L-ASNase specificity of the cytotoxicity observed upon exposure to 
the supernatants of Salmonella carrying pASN. It was also noted 
that the suppression of cell growth by the L-ASNase-containing 
bacterial supernatant was immediate irrespective of growth rate of 
the tumors, among those tested (Supplementary Figure S2).
Jurkat T cells treated with L-ASNase have been reported to undergo 
apoptosis.36 In order to assess the cell death mechanism of those 
tested cancer cell lines, we measured Annexin V, which is associated 
with apoptotic cell death. Total protein content was extracted from 
the cells exposed for 36 hours to the L-ASNase-containing bacte-
rial supernatant, and analyzed for Annexin V expression by western 
blotting. We observed a marked increase in the level of Annexin V 
in all cancer cells tested (Supplementary Figure S3a). This result was 
verified by immunofluorescence staining (Supplementary Figure 
S3b). L-ASNase-containing bacterial supernatant caused a consid-
erable accumulation of Annexin V on the cell surface compared to 
Figure 1  Cell death induced by the L-ASNase present in the bacterial culture medium. Salmonellae carrying pASN (SL/pASN) or parental vector GlmS+p32 
were grown in the presence of L-arabinose. The spent medium was collected after centrifugation and filtration, and concentrated to 50 mg protein/ml. 
Cytotoxicity (200 mg) was tested using cultured animal cells. The assay included 5 units of Leunase as control. Cell death was measured after 24, 48, and 
72 hours by MTT assay.41 Actual viable cells (A540 values) ± SD were plotted as function of time. Asterisks (*) indicate significant differences compared to 
phosphate-buffered saline (*P = 0.0097, ** P = 0.0119).
2.0
1.5
1.0
0.5
0.0
24 48 72
Vi
ab
le
 c
el
l (A
54
0)
2.0
1.5
1.0
0.5
0.0
Vi
ab
le
 c
el
l (A
54
0)
24 48 72
**
*
*
**
*
*
1.0
0.8
0.6
0.4
0.0
0.2V
ia
bl
e
 c
e
ll 
(A
54
0)
24 48 72
**
**
*
*
AsPC-1
*
*
PBS
SL
SL/pASN
Leunase
2.0
1.5
1.0
0.5
0.0
Vi
ab
le
 c
e
ll 
(A
54
0)
24 48 72
**
*
**
**
**
**
MC38
2.0
1.5
1.0
0.5
0.0
**
*
**
**
**
**
Vi
ab
le
 c
e
ll 
(A
54
0)
4T-1
HEK293 Jurkat T
Time (hours) Time (hours)
Time (hours) Time (hours)
24 48 72
Time (hours)
3L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors
K Kim et al.
Molecular Therapy — Oncolytics (2015) 15007© 2015 The American Society of Gene & Cell Therapy
phosphate-buffered saline (PBS). We concluded that the L-ASNase 
expressed and secreted by Salmonellae induces apoptotic cell 
death in cancer cells in vitro.
Antitumor efficacy of Salmonella-derived L-ASNase in mouse 
models
First, we measured the expression of L-ASNase under the control of 
PBAD in Salmonella targeted to MC38 tumors ectopically grafted in 
mice. 1 × 107 ΔppGpp S. typhimurium transformed with pASN was i.v. 
injected into the tumor-bearing mice and the L-ASNase was induced 
by intraperitoneal (i.p.) injection of L-arabinose 4 days postinocu-
lum (dpi). We have not noted any sign of serious local or systemic 
inflammatory reaction following the induction of cytotoxic antitu-
mor protein in intratumoral Salmonella at 3 dpi.9 Eight hours after 
the administration of L-arabinose, tumors (n = 2) were harvested, 
extracted, and the extracts separated by centrifugation into a super-
natant containing subcellular molecules and a pellet containing 
macromolecules including intact bacteria that were analyzed for the 
expression and secretion of L-ASNase by western blotting (Figure 2a 
L-ASNase-specific bands(32 kDa) were detected in the animals 
administered with L-arabinose. Moreover, a considerable amount of 
L-ASNase was detected in the supernatant, approximately a quar-
ter of the amount found in the pellet. This was further verified by 
immunohistochemical staining of the tumor tissue samples with 
L-ASNase-specific antibody (Figure 2b). Significantly elevated levels 
of L-ASNase were detected in mice treated with Salmonellae carrying 
pASN only after L-arabinose administration. It should be noted that 
L-ASNase-specific antibody also stained endogenous Salmonellae 
L-ASNase which shares 93% amino acid identity with E. coli L-ASNase 
(Salmonella alone), although the signal was weaker.
Subsequently, we assessed the antitumor efficacy of the 
Salmonellae transformed with pASN in mice bearing tumors: (i) 
MC38 tumors in C57BL/6 mice, (ii) 4T-1 tumors in BALB/c mice, 
and (iii) AsPC-1 tumors in BALB/c athymic nu−/nu−mice (Figure 3). 
Salmonellae carrying either pASN or GlmS+p were injected 
through the tail vain when the tumor reached ~120 mm3 (ref. 32). 
L-ASNase was induced by intraperitoneal injection of L-arabinose 
(60 mg/day/mouse) from 3 dpi, and changes in tumor size were 
recorded. The results showed the greatest antitumor efficacy with 
Salmonellae carrying L-ASNase induced by L-arabinose administra-
tion. We observed an antitumor effect with Salmonella monother-
apy, which was comparable to 4T-1 or smaller than that observed 
with Salmonella carrying pASN without L-arabinose administration 
(MC38), but measurably greater than PBS. At the end of the experi-
ment, the mean size of MC38 tumors (at 33 days), 4T-1 tumors (at 
35 days), and AsPC-1 tumors (at 45 days) treated with Salmonellae 
expressing L-ASNase was 463.7, 367.4, and 331 mm3, respectively, 
while tumors treated with bacteria carrying pASN without induc-
tion, that of bacteria carrying parental plasmid, and that of PBS all 
reached >1,000 mm3. Consequently, survival was substantially pro-
longed in the animals that received bacteria expressing L-ASNase 
compared to those in other groups (P < 0.001) (middle panels). 
Taken together, we concluded that the L-ASNase expressed and 
released from Salmonellae was effective at suppressing tumor 
growth in the mouse models used.
Correlation between antitumor efficacy and L-ASNase activity
Since L-ASNase was delivered by Salmonellae in this study, it was 
not possible to determine dose-dependent effect using the con-
ventional method. To this end, we employed mutant L-ASNases 
defective in enzyme activity. We chose two amino acid substitution 
mutants carrying Gly in place of Asn24 or Asp124, N24G and D124G 
substitution mutants, respectively, reported to have 45 and 3% 
activity compared to the wild-type protein, respectively.37 pASN 
carrying the above mutations in the asnB gene was constructed 
and named pASNN24G and pASND124G. ΔppGpp Salmonellae trans-
formed with these plasmids were grown in LB in the presence or 
absence of L-arabinose as described previously (Supplementary 
Figure S1). The bacterial culture was divided into bacterial pellet 
and medium, and assessed for the presence of ASNase by western 
blot (Figure 4a). The mutant L-ASNases, as well as the wild-type 
enzyme, were induced with L-arabinose and secreted into the 
medium. Subsequently, the bacterial supernatants containing the 
mutant L-ASNases were assayed for enzyme activity (Figure  4b). 
Mutant L-ASNases with N24G or D124G substitution showed 
Figure 2 Expression and release of L-ASNase from intratumoral 
Salmonellae carrying pASN. Mice bearing MC38 tumors were injected 
with Salmonellae carrying pASN(SL/pASN). L-ASNase was induced by 
i.p. injection of L-arabinose (60 mg), and the tumor tissues were excised 
8 hours after the induction, homogenized, and centrifuged (5,000 × g, 
5 minutes) to obtain the “supernatant” devoid of intact bacteria and 
the “pellet” containing macromolecules. 100 µg of pellet protein and 
supernatant protein were run on a 10% SDS PAGE gel and probed with 
L-ASNase-specific antibody (a). The same tissue samples were analyzed 
by confocal microcopy after immunofluorescence staining of L-ASNase 
(b). Salmonellae were stained in red and L-ASNase in green using specific 
antibodies.
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~50% and <10% activity, respectively, compared to the wild-
type control, as reported previously.37 Cytotoxicity was assessed 
in vitro by MTT assay using cultured cancer cells: MC38, 4T-1, and 
AsPC-1 (Figure 4c). Analysis of the relationship between L-ASNase 
activities and cancer cell viabilities yielded strong Pearson’s cor-
relations of r = −0.97567 (P < 0.0001) with MC38, r = −0.98707 
(P < 0.0001) with 4T-1, and r = −0.97700 (P < 0.0001) with AsPC-1 
(Supplementary Figure S4). To test the antitumor effect of mutant 
L-ASNases in vivo, MC38-bearing BL/6 mice were prepared as 
described previously (Figure 2) and injected through i.v. route 
with ΔppGpp Salmonellae transformed with either pASNN24G or 
pASND124G. For induction, mice were injected i.p. with L-arabinose 
at 3 dpi. The gross morphology of tumors extracted at 3 dpi are 
shown in Figure 5a, and quantification of tumor size in Figure 5b. 
Animal survival is shown in Figure 5c. A direct correlation between 
L-ASNase activity and regression of tumor size/extension of sur-
vival was noted in vivo.
Correlation between antitumor effect and local concentration of 
L-ASNase
To understand the distribution of L-ASNase expressed and secreted 
by tumor-targeted Salmonellae, we analyzed serum and tumor tissue 
in MC38-bearing mice by western blot using L-ASNase-specific anti-
body (Figure 6a) and by enzymatic activity assay (Figure 6b). Leunase 
(400 KU) injected intravenously was used as a control. Tissue samples 
were collected over time after administration of L-arabinose into 
mice treated with Salmonellae or after Leunase administration. In the 
animals treated with Leunase, a considerable amount of L-ASNase 
was detected in the serum at the early time point (4 hours) and 
diminished over time, but none was detected in the tumor tissue. 
By contrast, in mice treated with Salmonellae expressing L-ASNase, 
the protein was detected only in tumor tissue and increased dra-
matically as time progressed up to 48 hours. Accordingly, annexin 
V was induced in the tumor tissue only when the mice received 
Salmonellae expressing L-ASNase. Intravenous administration 
Figure 3 Antitumor effects of Salmonellae carrying L-ASNase in vivo. The antitumor effect of Salmonellae carrying pASN (1 × 107 colony forming unit) was 
measured using (a) MC38 tumors in C57BL/6 mice, (b) 4T-1 tumors in BALB/c mice, and (c) AsPC-1 tumors in BALB/c athymic nu-/nu- mice. The tumor-
bearing mice were treated with phosphate-buffered saline (n = 6), Salmonellae carrying empty vector, GlmS+p32 (n = 6), or Salmonellae carrying pASN(SL/
pASN) (n = 6 each group. L-arabinose (60 mg) was administered i.p. every day starting 4 days after the treatment with engineered S. typhimurium (SL/
pASN (Ara+)). Representative gross morphological changes are shown on the right. Changes in tumor size after the bacterial treatment are shown on 
the left. Error bars correspond to upper or lower 95% CIs. Kaplan-Meier survival curves of mice bearing MC38 (*P < 0.001, **P = 0.001, ***P = 0.005), 4T-1 
(*P < 0.001, **P = 0.0019) or AsPC-1 tumors (*P < 0.001, **P = 0.001, ***P = 0.003) are shown in the middle. Data represent mean ± SD, and asterisks (*) 
indicate significant differences compared to phosphate-buffered saline controls (*P < 0.05).
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of Leunase to MC38-bearing mice did not reduce tumor size 
(Supplementary Figure S5a and a high dose (400KU) shortened ani-
mal survival (Supplementary Figure S5b, which should be ascribed 
to the side effects.30 By contrast, a direct intratumoral injection of 
Leunase resulted in a notable reduction of tumor size (Figure 7a) (for 
Leunase 40KU versus control group, difference = 336 mm3, 95% CI 
= 220–451, P = 0.008; for Leunase 4KU versus control group, differ-
ence = 607 mm3, 95% CI = 532–681, P = 0.008), as it was detectable 
at the tumor tissues by western blotting (Figure 7). Taken together, 
we concluded that L-ASNase can be used to treat solid malignancies 
if delivered by a carrier such as Salmonellae to intratumoral sites so 
that a copious concentration is maintained in situ.
DISCUSSION
Many tumors exhibit deficiencies in the synthesis of one or more 
amino acids, forcing a reliance on extracellular pools of these amino 
acids for protein biosynthesis. Therefore, depletion of such amino 
acid(s) would provide cancer cell-selective therapy with few side 
effects. L-ASNase is used to mediate the degradation of such amino 
acids for therapeutic purposes; however, undesirable toxicity ham-
pers systemic injection.30 We have also seen a deleterious effect 
of high-dose L-ASNase injected intravenously (Supplementary 
Figure S5b). This could be caused by the fact that L-ASNase prevents 
several forms of glycosylation, including sialylation, in newly synthe-
sized proteins.38,39 In addition, E. coli L-ASNase possesses glutamin-
ase activity, which results in deprivation of L-glutamine.39 Whereas, 
bacterial tumor therapy circumvents the systemic injection of high-
dose L-ASNase, thereby avoiding systemic toxicity while maintain-
ing sufficient levels inside the tumor tissue.
Successful bacterial antitumor therapy, in which intratumoral bac-
teria are used to express anticancer proteins, requires certain provi-
sions, as follows. First, the antitumor protein should be expressed 
selectively at the tumor site, as demonstrated in this study. Since bac-
teria administered intravenously initially localize to reticuloendothe-
lial organs,8,9 the protein drugs should be expressed only when the 
bacteria have cleared reticuloendothelial organs and accumulated 
exclusively in the targeted tumor tissue; this normally occurs 3 days 
after administration. We have shown that controlled expression of 
cytotoxic proteins at 3 dpi does not cause any notable systemic tox-
icity.9 Second, the antitumor protein must be released. Fortunately, 
a significant fraction of the L-ASNase of E. coli origin was secreted 
from Salmonellae.  E. coli L-ASNase (EC2) is a periplasmic enzyme that 
contains a typical secretary signal peptide of 22 residues at its amino 
terminus. When the enzyme is secreted to the periplasm, the signal 
peptide is removed to yield a mature protein with an N-terminal leu-
cine residue.35 Proteins secreted into the periplasm tend to leak out 
through the bacterial outer membrane. Lastly, but most importantly, 
antitumor proteins should act on the cancer cell surface or the tumor 
microenvironment, rather than on intracellular targets. In the latter 
case, the barely permeable cell membrane remains a formidable 
barrier to efficacy. A widely used strategy uses cell-penetrating pep-
tides (CPPs) to improve intracellular uptake. Successful intracellular 
Figure 4 Expression and cytotoxic activity of mutant L-ASNases. (a) Expression of two amino acid substitution mutants (see text) and wild-type 
L-ASNases in the media supernatant and bacterial pellet upon induction with L-arabinose. See legend of Supplementary Figure S1 for details. (b) The 
spent media containing the mutant L-ASNases were assayed for enzyme activity. (c) Cytotoxicity associated with these mutant L-ASNases was measured 
in vitro using cultured MC38 (left), 4T-1 (middle), and AsPC-1 (right) by MTT assay. See legend of Figure1 for details. Data represent mean ± SD.
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delivery of antitumor proteins using this strategy requires optimiza-
tion of CPP for individual anticancer proteins.12 Given these consider-
ations, L-ASNase is an anticancer cargo protein that is appropriate for 
delivery to the tumor microenvironment by tumor-targeting bacteria.
We demonstrated a linear relationship between in vitro cytotox-
icity and in vivo tumor regression using mutant L-ASNases with 
varying levels of activity (Figures 4 and 5). The linear relationship 
revealed the dose-dependent effect of L-ASNase in vivo and was 
comparable with that determined using cultured cells in vitro. 
If bacterial therapy with ASNase-expressing Salmonellae was to be 
employed post-surgical elimination of the tumor, prognosis could 
be assessed based on the in vitro sensitivity of the cancer tissue to 
L-ASNase. In practice, bacterial therapy with Salmonella expressing 
L-ASNase, would be useful to treat cancer patients with multiple 
organ metastases since bacteria would be capable of targeting 
tumor of any kind with size as small as 100 mm.34
MATeRIAlS AND MeTHODS
Plasmid construction
DNA encoding ASNase II (asnB) was amplified from the genomic DNA of 
E. coli B strain (BL21)40 using two sets of primers: L-ASN1 (5′-GG GAA TTC 
ATGGAGTTT TTC AAA AAG-3′) and L-ASN2 (5′-GGG TCT AGA TTA GTA CTG 
ATT GAA GAT CTG CTG-3′). The 1,047 kb DNA fragment of asnB was inserted 
into GlmS+p32 using Eco RI and Xba I restriction enzyme sites to generate 
pASN. The mutant L-ASNases were generated by site-directed mutagen-
esis (Stratagene, San Diego, CA) using pASN and the following primers: P1, 
5′-GACTCCGCAACCAAATCTGGCTACACAGTGGGTAAAG-3′ for N24G; and P2, 
5′-ACGTCTATGAGCGCAGGCGGTCCATTCAACCTGT-3′ for D124G. All con-
structs were verified by automated DNA sequencing.
Bacterial growth conditions
Bacteria were grown in LB medium (Difco Laboratories) containing 1% NaCl. 
For solid support medium, 1.5%-bacto agar was included. All media were 
Figure 5 Antitumor effect of the mutant L-ASNases expressed by 
intratumoral Salmonellae. Salmonellae (1 × 107 colony forming unit) 
carrying pASN, pASNN24G, or pASND124G, were injected intravenously into 
C57BL/6 mice carrying MC38 tumors (n = 5 each group). (a) The change 
in gross morphology of the tumor tissue after bacterial treatment. 
(b) The changes in tumor size after bacterial treatment and (c) Kaplan–
Meier survival curves of the tumor-bearing mice. Data represent 
mean ± SD, and asterisks (*) indicate significant differences compared to 
phosphate-buffered saline (*P < 0.05).
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Figure 6 Distribution of L-ASNase in blood and tumor tissue. The 
C57BL/6 mice bearing MC38 tumors were treated with either 400 KU 
Leunase or Salmonellae carrying pASN (SKS1002/pASN) and analyzed 
for distribution of L-ASNase. In the latter case, L-ASNase was induced 
by a single administration of L-arabinose 4 days after bacterial injection 
(t = 0). Whole serum and tumor tissues (100 µg) were collected after 
the treatment and subjected to quantification of L-ASNase by western 
blotting (a). The same tumor tissues were analyzed for Annexin V and 
β-actin, the latter as a loading control. (b) L-ASNase activity measured 
using enzyme assay kit in the serum and tumor tissue in the mice treated 
as described above (n = 4 for each group). Data represent mean ± SD.
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supplemented with antibiotics as follows: ampicillin at 100 µg/ml, kanamy-
cin at 50 µg/ml, and chloramphenicol at 10 µg/ml.
Cell culture
MC38 and 4T-1 cell lines were grown in high-glucose Dulbecco’s modified 
Eagle medium, HEK293 in EME medium, and AsPC1 and Jurkat T in RPMI1640 
medium, containing 10% FBS and 1% penicillin-streptomycin.
Protein (L-ASNase) preparation
The spent bacterial media and bacterial pellets were prepared as follows 
after centrifugation (5,000 ×g, 5 minutes) and filtration (0.45 µm): the pellets 
were lysed by sonication in lysis buffer (10 mmol/l lysozyme, 10% sodium 
dodecyl sulfate (SDS)), and the supernatants were filtered (0.22 µm pore 
filter) and concentrated using Centricon devices (AmiconR Ultra, 10K pore 
filter, Millipore). The proteins were precipitated with 10% trichloroacetic 
acid (1 hour, 4 °C) and dissolved in PBS. Leunase was purchased from Kyowa 
Hakko Kirin, Japan.
Western analysis
Mammalian cell lines and tumor tissues were lysed by sonication in RIPA 
buffer (50 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1% NP40, 0.5% sodium 
deoxycholate, and 0.1% SDS) containing protease inhibitors (protease 
inhibitor mixture; Roche Applied Science). Tumor tissue were extracted, 
homogenized with a motor-driven tissue homogenizer (Ika-Werke, Staufen, 
Germany), and separated to supernatant and pellet by centrifugation (5,000 
× g, 5 minutes). The pellets were lysed by sonication as described above. The 
supernatants were treated with 10% trichloroacetic acid (1 hour, 4 °C) for pre-
cipitation of proteins. For western blot analysis, protein samples were boiled 
for 5 minutes, separated by 10% SDS-PAGE, and transferred to nitrocellulose 
membrane (Amersham Biosciences). The membrane was blocked with 5% 
skim milk and probed with a rabbit anti-L-ASNase antibody (1:1,000; Abcam), 
rabbit anti-Annexin V antibody (1:2,000, Abcam), or mouse anti-β-Actin 
antibody (1:5,000, Santa Cruz) at 4 °C overnight. The membrane was then 
incubated with anti-mouse or anti-rabbit IgG linked to horseradish peroxi-
dase (Sigma-Aldrich, UK) for 1 hour and bound proteins were visualized by 
ECL (Amersham Biosciences).
Cell viability assay (MTT)
The MTT assay was performed to evaluate cell proliferation. The cells (3 × 103 
per well) were seeded into 96-well culture plates in 100 µl medium at 37 °C 
with 5% CO2. After overnight incubation, the supernatant was removed and 
fresh medium was added. The cells were incubated with concentrated bac-
terial supernatant (0.2 mg/ml) and the number of live cells was determined 
using MTT assay kit (Sigma-Aldrich, St. Louis, MO).
Immunofluorescence and confocal microscopy
The cells were grown on sterilized glass cover slips, fixed with 4% parafor-
maldehyde, and blocked with 0.1% BSA (bovine serum albumin) in PBS. 
Subsequently, the samples were stained with rabbit anti-Annexin Va ntibody 
(1:200, Abcam) in PBS and Alexa 488-conjugated secondary antibody (1:500, 
Invitrogen). The samples were also stained with Texas Red-X phalloidin (1:500, 
Invitrogen) and DAPI/antifade (1:200, Invitrogen). Images were captured with 
a Bio-Rad confocal microscope (Bio-Rad laboratories, Hercules, CA).
Tissue immunofluorescence staining
Tumor tissues were fixed with 4% paraformaldehyde in PBS overnight at 
room temperature, and embedded and frozen using optical optimal cutting 
temperature compound (Tissue-Tek). The tumors were sliced into 6-µm thick 
sections using a microtome-cryostat. The tissue sections were collected on 
aminopropyltriethoxysilane-coated slides. The slides were washed using PBS 
(pH7.4) for complete removal of the optimal cutting temperature compound 
and incubated with primary antibodies, rabbit anti-L-ASNase antibody (1:100, 
Abcam), and mouse anti-Salmonella antibody (1:100, Abcam), overnight at 4 
°C. Alexa 488-conjugated goat anti-rabbit antibody (1:100) and Alexa 568-con-
jugated goat anti-mouse antibody (1:100) were used as secondary antibodies. 
The samples were mounted with DAPI/antifade (1:200, Invitrogen).
Animal experiments
Five- to 6-week-old male mice (20–30 g body weight) were purchased 
from Samtako Company, Korea. All animal care, experiments, and eutha-
nasia were performed in accordance with the protocols approved by the 
Chonnam National University Animal Research Committee. Animals were 
anesthetized with isoflurane (2%) for imaging or a mixture of ketamine 
(200 mg kg−1) and xylasine (10 mg kg−1) for surgery. Mice carrying subcuta-
neous tumors were generated as follows: tumor cells cultured in vitro were 
harvested, suspended in 100 µl PBS, and injected subcutaneously into the 
right thigh (1 × 106 cells for 4T-1 and MC38, and 1 × 107 cells for AsPC1). 
Tumor volumes (mm3) were estimated using the formula (L × H × W)/2 where 
L is the length, W is the width, and H is the height of the tumor in millime-
ters. 1 × 107 ΔppGpp S. typhimurium transformed with pASN suspended in 
PBS was injected through the tail vain when the tumor reached ~120 mm3. 
L-ASNase was induced by intraperitoneal (i.p.) injection of L-arabinose 4 days 
postinoculum (dpi) (60 mg/day/mouse).
Injection of bacteria into animals
S. typhimurium suspended in 100 µl PBS were injected intravenously into 
tumor-bearing mice through the lateral tail vein using an l cc insulin syringe.
Determination of L-ASNase activity
Bacterial supernatants of native and mutants L-ASNase were prepared as 
concentrated forms for the enzymatic assay. Serum samples were directly 
used for the enzyme assay. Tumor tissue samples were extracted by the  4 vol-
umes of assay buffer in Asparaginase Activity Assay kit (Abcam, ab107922), 
Figure 7 Antitumor effect of Leunase after intratumoral injection. Leunase 
was directly injected into MC38 tumors in C57BL/6 mice (n = 5) at 4 KU 
and 40 KU daily for 3 days. On day 4, animals were sacrificed and tumor 
size was estimated as described in the legend of Figure 5 (a). (b) Gross 
morphology of the tumor tissues. (c) Distribution of L-ASNase in blood 
and tumor tissue after the Leunase treatment by western blotting. Data 
represent mean ± SD, and asterisks (*) indicate significant differences 
compared to phosphate-buffered saline (*P < 0.05).
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and insoluble materials were removed by the centrifugation. Levels of 
L-ASNase enzymatic activity in the bacterial supernatants (100 µg), serum 
(10 µl), and tumor tissues (100 µg) were assessed with the Asparatinase 
Activity assay kit, for a quantitative enzyme assay.
Correlative analysis
Pearson’s correlation coefficients in Supplementary Figure S5 were com-
puted for the relationship between L-ASNase activities and cell viabilities 
using GraphPad Prism 5.01, including P values for the one-tailed test of 
significance
Statistical analysis
Statistical analysis was performed using the SPSS 18.0 statistical package 
(SPSS, Chicago, IL). A two-tailed Student’s t-test was used to assess the sta-
tistical significance of tumor growth differences between treatment groups. 
P < 0.05 was considered statistically significant.
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